The phase III ALEX trial, conducted with 303 treatment-naive, ALK-rearranged advanced NSCLC patients, compared alectinib at 600 mg twice daily (n = 152) with crizotinib at 250 mg twice daily (n = 151) in first-line treatment [34,35,36,37]. Here, ALK is linked to non-small cell lung carcinoma.